Incyte Corp. stock underperforms Thursday when compared to competitors despite daily gains

This was the stock's second consecutive day of gains.

Bernstein Sticks to Their Hold Rating for Incyte (INCY)

In a report released yesterday, from Bernstein maintained a Hold rating on Incyte. The company’s shares closed yesterday at $95.59. Unlock trusted, data-backed investing tools with TipRanks Premium, ...

Mirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at E…

Mirum and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted ...
The Globe and Mail

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Tempus AI, Inc. Class A (TEM) and Incyte (INCY)

In a report released today, Emily Field from Barclays maintained a Buy rating on Eli Lilly & Co, with a price target of $1400.00. The company’s shares closed last Friday at $1105.00. According to ...